Donanemab treatment effect by baseline tau burden and disease severity: Observations from the TRAILBLAZER-ALZ 2 trial.
- DOI
- 10.1002/alz.71577
- Published
- 2026 Jun
- Container
- Alzheimer's & dementia : the journal of the Alzheimer's Association
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1002/alz.71577,
title = {Donanemab treatment effect by baseline tau burden and disease severity: Observations from the TRAILBLAZER-ALZ 2 trial.},
author = {Raket LL and Lu M and Evans CD and Zimmer JA and Sparks J and Collins EC and Shcherbinin S and Wang H and Nery ESM and Epelbaum S and Dell'Agnello G and Brooks DA and Sims JR and Mintun MA},
year = {2026},
journal = {Alzheimer's \& dementia : the journal of the Alzheimer's Association},
doi = {10.1002/alz.71577},
url = {https://doi.org/10.1002/alz.71577}
}RIS
TY - JOUR TI - Donanemab treatment effect by baseline tau burden and disease severity: Observations from the TRAILBLAZER-ALZ 2 trial. AU - Raket LL AU - Lu M AU - Evans CD AU - Zimmer JA AU - Sparks J AU - Collins EC AU - Shcherbinin S AU - Wang H AU - Nery ESM AU - Epelbaum S AU - Dell'Agnello G AU - Brooks DA AU - Sims JR AU - Mintun MA PY - 2026 JO - Alzheimer's & dementia : the journal of the Alzheimer's Association DO - 10.1002/alz.71577 UR - https://doi.org/10.1002/alz.71577 ER -
APA
LL, R., M, L., CD, E., JA, Z., J, S., EC, C., S, S., H, W., ESM, N., S, E., G, D., DA, B., JR, S., & MA, M. (2026). Donanemab treatment effect by baseline tau burden and disease severity: Observations from the TRAILBLAZER-ALZ 2 trial.. Alzheimer's & dementia : the journal of the Alzheimer's Association. https://doi.org/10.1002/alz.71577
Source records
- pubmed · retrieved 2026-09-25T07:59:50.299Z